Key result
Soluble ST2 follows a biphasic trajectory after TTVI, rising at discharge then falling through 12 months.
Why the study?
Does transcatheter tricuspid valve intervention alter longitudinal trajectories of soluble ST2 and other stress and inflammation biomarkers in elderly patients with advanced right heart failure?
Cohort (n=135)
No
Does transcatheter tricuspid valve intervention alter longitudinal trajectories of soluble ST2 and other stress and inflammation biomarkers in elderly patients with advanced right heart failure?
Answers are grounded in this paper and cite their sources.
Soluble ST2 demonstrates a consistent biphasic longitudinal decline up to 12 months following transcatheter tricuspid valve intervention, suggesting its potential utility as a renal-independent biomarker for monitoring biological response in advanced right heart failure.
Background Biomarker trajectories following transcatheter tricuspid valve intervention (TTVI) remain insufficiently characterized. Interpretation of natriuretic peptides in this population is challenging due to frequent renal dysfunction and cardiorenal syndrome. Soluble ST2 (sST2) provides prognostic information independent of renal function and natriuretic peptides. Complementary biomarkers reflecting systemic stress, inflammation, and myocardial injury were assessed in parallel to contextualize biological response after TTVI. Purpose To characterize serial changes of sST2 and compare its longitudinal dynamics with other stress and inflammation biomarkers after TTVI. Methods In a prospective single-centre cohort, 135 patients undergoing TTVI were included. sST2, GDF-15, suPAR, H-FABP, and NT-proANP were measured at baseline, discharge, 3 months, and 12 months. Longitudinal changes were analysed using paired non-parametric comparisons. Results The cohort was elderly (median age 82 years), with high prevalence of atrial fibrillation and advanced right heart failure. sST2 exhibited a distinct biphasic trajectory, with significant increase from baseline to discharge (n=135; p=0.004), followed by significant reduction at 3 months (n=124; p=0.003) and sustained decline at 12 months (n=82; p<0.0001).GDF-15 showed no significant longitudinal change. suPAR demonstrated early reduction at discharge (p<0.001) and 3 months (p=0.004), without sustained decline at 12 months (p=0.895). H-FABP decreased only at 12 months (p=0.007), whereas NT-proANP showed no consistent dynamic pattern. Conclusion Among the biomarkers assessed, sST2 exhibited the most consistent longitudinal trajectory following TTVI. This dynamic pattern suggests potential utility for monitoring biological response in this population and warrants further validation in independent cohorts.
No takes yet. Share an insight, caveat, or question.
Edlinger et al. (2026) conducted a cohort in Severe tricuspid regurgitation / advanced right heart failure undergoing transcatheter tricuspid valve intervention (TTVI) (n=135). Transcatheter tricuspid valve intervention (TTVI) and serial sST2 measurement vs. Baseline biomarker levels and other stress/inflammation biomarkers (GDF-15, suPAR, H-FABP, NT-proANP) was evaluated on Longitudinal changes in soluble ST2 (sST2) from baseline to discharge, 3 months, and 12 months (p=<0.0001). Soluble ST2 showed a biphasic trajectory after TTVI, increasing at discharge before declining at 3 months and 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: